vs
Douglas Elliman Inc.（DOUG）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Douglas Elliman Inc.的季度营收约是Orthofix Medical Inc.的1.1倍（$245.4M vs $219.9M），Douglas Elliman Inc.净利率更高（27.9% vs -1.0%，领先28.9%），Orthofix Medical Inc.同比增速更快（2.0% vs 0.9%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-14.7M），过去两年Douglas Elliman Inc.的营收复合增速更高（10.7% vs 8.0%）
Douglas Elliman Inc.是美国领先的住宅房地产经纪企业，提供高端房产买卖、租赁、物业管理及相关咨询服务，核心业务覆盖纽约、加州、佛罗里达、得克萨斯等都会区，主要服务高净值客户群体。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
DOUG vs OFIX — 直观对比
营收规模更大
DOUG
是对方的1.1倍
$219.9M
营收增速更快
OFIX
高出1.1%
0.9%
净利率更高
DOUG
高出28.9%
-1.0%
自由现金流更多
OFIX
多$31.5M
$-14.7M
两年增速更快
DOUG
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $245.4M | $219.9M |
| 净利润 | $68.6M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 27.3% | 0.2% |
| 净利率 | 27.9% | -1.0% |
| 营收同比 | 0.9% | 2.0% |
| 净利润同比 | 1243.4% | 92.4% |
| 每股收益（稀释后） | $0.80 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOUGOFIX
| Q4 25 | $245.4M | $219.9M | ||
| Q3 25 | $262.8M | $205.6M | ||
| Q2 25 | $271.4M | $203.1M | ||
| Q1 25 | $253.4M | $193.6M | ||
| Q4 24 | $243.3M | $215.7M | ||
| Q3 24 | $266.3M | $196.6M | ||
| Q2 24 | $285.8M | $198.6M | ||
| Q1 24 | $200.2M | $188.6M |
净利润DOUGOFIX
| Q4 25 | $68.6M | $-2.2M | ||
| Q3 25 | $-24.7M | $-22.8M | ||
| Q2 25 | $-22.7M | $-14.1M | ||
| Q1 25 | $-6.0M | $-53.1M | ||
| Q4 24 | $-6.0M | $-29.1M | ||
| Q3 24 | $-27.2M | $-27.4M | ||
| Q2 24 | $-1.7M | $-33.4M | ||
| Q1 24 | $-41.5M | $-36.0M |
毛利率DOUGOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率DOUGOFIX
| Q4 25 | 27.3% | 0.2% | ||
| Q3 25 | -4.1% | -8.3% | ||
| Q2 25 | -2.0% | -7.9% | ||
| Q1 25 | -2.1% | -25.2% | ||
| Q4 24 | -6.7% | -5.3% | ||
| Q3 24 | -2.8% | -9.6% | ||
| Q2 24 | -1.3% | -12.5% | ||
| Q1 24 | -20.7% | -15.6% |
净利率DOUGOFIX
| Q4 25 | 27.9% | -1.0% | ||
| Q3 25 | -9.4% | -11.1% | ||
| Q2 25 | -8.4% | -6.9% | ||
| Q1 25 | -2.4% | -27.4% | ||
| Q4 24 | -2.5% | -13.5% | ||
| Q3 24 | -10.2% | -13.9% | ||
| Q2 24 | -0.6% | -16.8% | ||
| Q1 24 | -20.7% | -19.1% |
每股收益（稀释后）DOUGOFIX
| Q4 25 | $0.80 | $-0.05 | ||
| Q3 25 | $-0.29 | $-0.57 | ||
| Q2 25 | $-0.27 | $-0.36 | ||
| Q1 25 | $-0.07 | $-1.35 | ||
| Q4 24 | $-0.06 | $-0.76 | ||
| Q3 24 | $-0.33 | $-0.71 | ||
| Q2 24 | $-0.02 | $-0.88 | ||
| Q1 24 | $-0.50 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $115.5M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $183.9M | $450.0M |
| 总资产 | $444.4M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOUGOFIX
| Q4 25 | $115.5M | $82.0M | ||
| Q3 25 | $143.0M | $62.9M | ||
| Q2 25 | $136.3M | $65.6M | ||
| Q1 25 | $136.8M | $58.0M | ||
| Q4 24 | $145.5M | $83.2M | ||
| Q3 24 | $151.4M | $30.1M | ||
| Q2 24 | $92.9M | $26.4M | ||
| Q1 24 | $91.5M | $27.0M |
总债务DOUGOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益DOUGOFIX
| Q4 25 | $183.9M | $450.0M | ||
| Q3 25 | $115.1M | $442.5M | ||
| Q2 25 | $137.6M | $458.3M | ||
| Q1 25 | $158.2M | $458.3M | ||
| Q4 24 | $162.2M | $503.1M | ||
| Q3 24 | $173.6M | $525.9M | ||
| Q2 24 | $196.9M | $546.0M | ||
| Q1 24 | $195.1M | $570.3M |
总资产DOUGOFIX
| Q4 25 | $444.4M | $850.6M | ||
| Q3 25 | $480.6M | $832.6M | ||
| Q2 25 | $489.0M | $837.2M | ||
| Q1 25 | $493.9M | $823.1M | ||
| Q4 24 | $493.9M | $893.3M | ||
| Q3 24 | $502.7M | $867.9M | ||
| Q2 24 | $463.9M | $882.0M | ||
| Q1 24 | $461.1M | $906.0M |
负债/权益比DOUGOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.7M | $16.8M |
| 自由现金流率自由现金流/营收 | -6.0% | 7.6% |
| 资本支出强度资本支出/营收 | 0.1% | 4.9% |
| 现金转化率经营现金流/净利润 | -0.21× | — |
| 过去12个月自由现金流最近4个季度 | $-17.2M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流DOUGOFIX
| Q4 25 | $-14.4M | $27.7M | ||
| Q3 25 | $5.5M | $12.4M | ||
| Q2 25 | $642.0K | $11.6M | ||
| Q1 25 | $-5.6M | $-18.4M | ||
| Q4 24 | $-9.0M | $23.7M | ||
| Q3 24 | $9.0M | $11.7M | ||
| Q2 24 | $1.3M | $9.0M | ||
| Q1 24 | $-27.3M | $-18.6M |
自由现金流DOUGOFIX
| Q4 25 | $-14.7M | $16.8M | ||
| Q3 25 | $4.7M | $2.5M | ||
| Q2 25 | $-575.0K | $4.5M | ||
| Q1 25 | $-6.7M | $-25.1M | ||
| Q4 24 | $-10.2M | $15.2M | ||
| Q3 24 | $7.7M | $6.3M | ||
| Q2 24 | $432.0K | $-360.0K | ||
| Q1 24 | $-29.4M | $-29.1M |
自由现金流率DOUGOFIX
| Q4 25 | -6.0% | 7.6% | ||
| Q3 25 | 1.8% | 1.2% | ||
| Q2 25 | -0.2% | 2.2% | ||
| Q1 25 | -2.6% | -13.0% | ||
| Q4 24 | -4.2% | 7.0% | ||
| Q3 24 | 2.9% | 3.2% | ||
| Q2 24 | 0.2% | -0.2% | ||
| Q1 24 | -14.7% | -15.4% |
资本支出强度DOUGOFIX
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | 0.3% | 4.8% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | 0.4% | 3.5% | ||
| Q4 24 | 0.5% | 4.0% | ||
| Q3 24 | 0.5% | 2.7% | ||
| Q2 24 | 0.3% | 4.7% | ||
| Q1 24 | 1.0% | 5.6% |
现金转化率DOUGOFIX
| Q4 25 | -0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
